The Hill (1/7, Beard) reported in its
"Healthwatch" blog that Rep. Henry Waxman (D-CA) commemorated the
30th anniversary of the Orphan Drug Act's passage, saying, "By definition,
the market for a drug for rare disease was too small to attract drug companies
to do the research and go through [the US Food and Drug Administration's]
approval process." The Act, "signed into law by President Reagan on
Jan. 4, 1983,...created financial incentives for products that treated those
afflicted with rare diseases." According to the National Organization for
Rare Disorders, "more than 400 treatments have been approved by the
FDA" in the thirty years since the Act was passed.
DIA Daily is a digest of the most important news selected from thousands of sources by the editors of BulletinHealthcare. The presence of content or advertising does not endorse, nor imply endorsement of, any products or services by the Drug Information Association. Neither BulletinHealthcare nor the Drug Information Association is liable for the use of or reliance on any information contained in this briefing.
If you would like more information about, or have a question pertaining to, DIA Membership and its benefits, please email membership@diahome.org.Click here to check your membership status.
Drug Information Association | 800 Enterprise Road, Suite 200 | Horsham, PA 19044
Copyright © 2012 by BulletinHealthcare| 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191
No comments:
Post a Comment